Dealmaking in the biopharma sector may have trended lower in
early 2022, but activity could rebound into 2023 as the economic
outlook becomes clearer.
Big pharma certainly seems to have returned to the table in the
latter half of 2022, with notable acquisitions by Pfizer of
Biohaven Pharmaceuticals and Global Blood Therapeutics and
Amgen's acquisition of ChemoCentryx and recently announced deal
to buy Horizon Therapeutics for $27.8 billion.
Even J.P. Morgan is aiming for success in the sector. The bank
launched its new life science private equity arm in
November with an eye on gene therapy and autoimmune fields, among
others within the sector1.
Yet, M&A activity in the biopharma sector has not returned
to 2021 levels, which was a record year across all industries. For
life science, which includes biopharma, medtech and pharma
services, the sector experienced healthy activity in 2021 with 145
deals valued at $40 billion, according to Bain & Company's
2022